[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100504403":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":36,"locations":45,"responsibleParty":83,"collaborators":86,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":10,"eligibilityCriteria":95,"healthyVolunteers":96,"sex":97,"minAge":98,"maxAge":10,"enrollmentInfo":99,"targetDuration":10,"studyType":102,"phases":10,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Fudan University","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"pNETs",null,"Patients with pancreatic neuroendocrine tumors (pNETs). The prospective cases enrolled by the sub-center shall strictly comply with the study's inclusion\u002Fexclusion criteria, consistent with the main center, and no independent adjustment of the enrollment criteria is allowed.",[13],"Diagnostic Test: Blood collection",{"label":15,"type":10,"description":16,"interventionNames":17},"Healthy","Healthy volunteers. The prospective cases enrolled by the sub-center shall strictly comply with the study's inclusion\u002Fexclusion criteria, consistent with the main center, and no independent adjustment of the enrollment criteria is allowed.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"PDAC","Patients with pancreatic ductal adenocarcinoma (PDAC) . The prospective cases enrolled by the sub-center shall strictly comply with the study's inclusion\u002Fexclusion criteria, consistent with the main center, and no independent adjustment of the enrollment criteria is allowed.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"SPT","Patients with solid pseudopapillary tumor (SPT) of pancreas. The prospective cases enrolled by the sub-center shall strictly comply with the study's inclusion\u002Fexclusion criteria, consistent with the main center, and no independent adjustment of the enrollment criteria is allowed.",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"DIAGNOSTIC_TEST","Blood collection","Blood collection for fragmentomic profiles of plasma cell-free DNA. The sub-center shall use the same blood collection consumables (EDTA anticoagulant vacutainer tubes) and blood collection volume (10ml) as the main center; plasma separation shall be completed within 2 hours after blood collection, and all operations shall comply with the study's unified SOP.",[15,19,23,9],[33],{"name":34,"affiliation":5,"role":35},"Xianjun Yu, MD, PhD","PRINCIPAL_INVESTIGATOR",[37,41],{"name":34,"role":38,"phone":39,"phoneExt":10,"email":40},"CONTACT","021-64175590-88503","yuxianjun@fudanpci.org",{"name":42,"role":38,"phone":43,"phoneExt":10,"email":44},"Shunrong Ji, MD, PhD","13788993956","jishunrong@fudanpci.org",[46,68],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Fudan University shanghai cancer center","RECRUITING","Shanghai","Shanghai Municipality","200032","China","CN",{"type":55,"coordinates":56},"Point",[57,58],121.45806,31.22222,{"lat":58,"lon":57},[61,63,65],{"name":62,"role":38,"phone":43,"phoneExt":10,"email":10},"Shunrong Ji, MD,PhD",{"name":64,"role":35,"phone":10,"phoneExt":10,"email":10},"Xianjun Yu",{"name":66,"role":67,"phone":10,"phoneExt":10,"email":10},"Shunrong Ji","SUB_INVESTIGATOR",{"facility":69,"status":48,"city":70,"state":71,"zip":72,"country":52,"countryCode":53,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"West China Hospital, Sichuan University","Chengdu","Sichuan","610041",{"type":55,"coordinates":74},[75,76],104.06667,30.66667,{"lat":76,"lon":75},[79],{"name":80,"role":38,"phone":81,"phoneExt":10,"email":82},"Doctor","086-18019216797","zwh0105@126.com",{"type":35,"investigatorFullName":84,"investigatorTitle":85,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Xian-Jun Yu","President of Shanghai Pancreatic Cancer Institute",[87],{"name":88,"class":6},"West China Hospital","100504403","plasma-cfdna-fragmentomics-for-early-pnet-detection-and-differential-diagnosis-of-solid-pancreatic-tumors-100504403",false,"NCT05847855","Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors","A Prospective Study of Plasma Cell-free DNA Fragmentomics for Early Detection of Pancreatic Neuroendocrine Tumors and Differential Diagnosis of Solid Pancreatic Tumors","Inclusion Criteria:\n\n* Age 18 and above, regardless of gender;\n* Histopathological diagnosis with non-functional pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor;\n* Not receiving any anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;\n* No obvious surgical contraindications;\n* Able to comply with research plans, follow-up plans, and other protocol requirements;\n* Voluntary participation and signed informed consent.\n\nExclusion Criteria:\n\n* Pathological diagnosis was not pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor;\n* Currently diagnosed with other types of tumors or any cancer history;\n* Diagnosed with familial syndromes;\n* Receiving anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;\n* Ongoing fever or recipient of anti-inflammation therapy within 14 days prior to study blood draw;\n* Recipient of blood transfusion within 30 days prior to study blood draw;\n* Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant;\n* Poor health condition and not suitable for blood draw;\n* Any other disease\u002Fcondition deemed not suitable for study enrollment by researcher.",true,"ALL","18 Years",{"count":100,"type":101},1000,"ESTIMATED","OBSERVATIONAL","This prospective study aims to evaluate the sensitivity and specificity of an integrated model using fragmentomic profiles of plasma cell-free DNA for early detection of pancreatic neuroendocrine tumors and differential diagnosis of solid pancreatic tumors.",[105,106],"Pancreatic Neuroendocrine Tumor","Solid Pancreatic Neoplasms",[108,109,110,111,112],"Pancreatic neuroendocrine tumor","cell-free DNA","fragmentomics","early detection","Solid pancreatic neoplasms","2026-03-23",{"date":115,"type":116},"2026-03-25","ACTUAL",{"date":118,"type":116},"2023-02-27",{"date":120,"type":101},"2026-06-30",{"name":5,"class":6},2]